Add BrightSurf on Google Email

Impact Journals LLC


Why some breast cancer treatments stop working

A new review highlights how breast cancer cells change their communication and growth patterns, helping tumors survive, spread, and resist treatment. The review explores disrupted signaling pathways, including PI3K/Akt/mTOR and RAS/RAF/MEK/ERK, which can promote tumor progression and resistance to treatment.

SourceImpact Journals LLC·JournalOncotarget·TypeSystematic review·DateMar 25, 2025

WIN Consortium leading the future of precision cancer medicine

The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateMar 18, 2025

New study suggests panitumumab with low-dose capecitabine as a safer, effective maintenance treatment for advanced colorectal cancer

Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateFeb 18, 2025